Actively Recruiting
Pharmacokinetic and Safety Study of GOPRELTO4% and NUMBRINO24% Nasal Solutions for Local Anesthesia in Pediatric Patients Aged 12 to Under 18 Years
Led by LXO Ireland · Updated on 2026-10-16
40
Participants Needed
6
Research Sites
4 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the pharmacokinetics, safety, and tolerability of two anesthetic nasal solutions, GOPRELTO4% and NUMBRINO24%, in pediatric adolescents aged 12 to under 18 years. These anesthetics are used for diagnostic procedures and surgeries involving the mucous membranes of the nasal cavities. The study aims to determine appropriate dosing and assess how these drugs behave in the body when given as a single topical dose. Participants will receive a single dose of either GOPRELTO4% or NUMBRINO24% nasal solution applied by study staff using saturated cottonoid pledgets placed in both nostrils. The dose will be up to 160 mg depending on the participants weight. This is an open-label, non-randomized, two-arm study with sequential treatment of each nasal solution. During the study, participants will undergo vital sign monitoring including blood pressure, heart rate, and respiratory rate every 5 minutes for 90 minutes after application. Other assessments include physical exams, electrocardiograms, pulse oximetry, and blood sampling to measure drug levels at multiple time points up to 8 hours post-dose. Safety and adverse events will be tracked through Day 10. The total study duration for participants will cover screening, dosing, monitoring, and follow-up assessments.
CONDITIONS
Brief Title
Pharmacokinetics, Safety, and Tolerability Study of GOPRELTO® Nasal Solution and NUMBRINO™ Nasal Solution
Research Team
R
Robert Puchlaski, M.D
W
Wayne J Harsha, M.D
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here